The findings highlight the potential benefits of newer biologics targeting IL-12, IL-23, and IL-17 while also raising ...

The EU medicines regulator on Friday rejected Eli Lilly's Alzheimer's drug, saying the treatment's ability to slow cognitive ...

The European Union's drugs regulator on Friday rejected Eli Lilly's Alzheimer's drug, saying the treatment's small impact on ...

Biogen enhances its portfolio and margins amidst market challenges and competition. Click here to find out why BIIB stock is ...

But, of course, young people themselves need to be offered a place at the table to make the changes they need for their own ...

Shares of Biogen Inc. BIIB slipped 1.40% to $138.37 Friday, on what proved to be an all-around rough trading session for the ...

With its move to MIT’s Volpe Center in Kendall Square, the drugmaker is consolidating its local footprint from three ...

Cambridge-based biotechnology company Biogen Inc. announced Monday that it will move its global headquarters to a new ...

Lilly said it is planning to request a re-examination of the CHMP's appraisal of Kisunla, pointing out that the drug has ...

The facility, which is set to open amid Biogen’s 50th anniversary, will integrate research and development, technical ...

Biogen Inc. plans to move its headquarters into a 16-story Kendall Square tower to be developed by MIT and BioMed Realty ...